HUGE BRAVO to the Supreme Court for unanimously ruling that the Myriad
Genetics' patents on the BRCA-1 and BRCA-2 genes are invalid. This will
open the doors for more competition in testing for the cancer-related
genetic mutations, which should in turn lower the costs for these tests,
and make them more widely available for those who choose
to be tested.